Baxter International Inc. (NYSE:BAX) Receives $77.69 Consensus Target Price from Analysts

Baxter International Inc. (NYSE:BAXGet Rating) has been assigned a consensus rating of “Hold” from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $77.69.

A number of research firms recently issued reports on BAX. Stifel Nicolaus reduced their price objective on Baxter International from $85.00 to $75.00 in a research report on Monday, July 18th. Cowen reduced their price objective on Baxter International from $95.00 to $70.00 in a research report on Friday, July 29th. Wells Fargo & Company lowered Baxter International from an “overweight” rating to an “equal weight” rating and set a $71.00 price target for the company. in a research report on Friday, June 24th. Cowen reduced their price target on Baxter International from $95.00 to $70.00 in a research report on Friday, July 29th. Finally, Morgan Stanley reduced their price target on Baxter International from $86.00 to $72.00 and set an “overweight” rating for the company in a research report on Friday, July 29th.

Baxter International Price Performance

Shares of BAX opened at $55.37 on Friday. Baxter International has a 52 week low of $54.45 and a 52 week high of $89.70. The firm has a market cap of $27.88 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 2.05 and a beta of 0.60. The company has a current ratio of 2.01, a quick ratio of 1.33 and a debt-to-equity ratio of 1.83. The stock has a 50 day moving average of $59.90 and a 200-day moving average of $68.42.

Baxter International (NYSE:BAXGet Rating) last released its quarterly earnings data on Thursday, July 28th. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.87. Baxter International had a return on equity of 21.75% and a net margin of 7.12%. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.88 billion. During the same quarter in the previous year, the firm posted $0.80 EPS. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, analysts forecast that Baxter International will post 3.63 EPS for the current year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Friday, September 2nd will be paid a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date is Thursday, September 1st. Baxter International’s dividend payout ratio is presently 58.00%.

Institutional Trading of Baxter International

Hedge funds and other institutional investors have recently modified their holdings of the company. Rosenberg Matthew Hamilton raised its stake in shares of Baxter International by 252.8% in the 1st quarter. Rosenberg Matthew Hamilton now owns 441 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 316 shares in the last quarter. Bogart Wealth LLC raised its position in shares of Baxter International by 500.0% during the second quarter. Bogart Wealth LLC now owns 600 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 500 shares during the period. CoreCap Advisors LLC acquired a new stake in shares of Baxter International during the second quarter worth $43,000. Herold Advisors Inc. acquired a new stake in shares of Baxter International during the first quarter worth $47,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Baxter International during the fourth quarter worth $76,000. Institutional investors own 84.69% of the company’s stock.

About Baxter International

(Get Rating)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.

Featured Stories

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.